Key terms
About RZLT
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RZLT news
Today
12:35am ET
Optimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment Prospects
Mar 11
5:12pm ET
Rezolute’s Preclinical Success with New Hypoglycemia Treatment
Mar 07
6:30am ET
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), iTeos Therapeutics (ITOS) and Rezolute (RZLT)
Mar 06
7:39am ET
Rezolute reports validation of potential use of RZ358
Feb 20
1:55pm ET
Rezolute participates in a conference call with Cantor Fitzgerald
Feb 20
1:03pm ET
Rezolute participates in a conference call with Cantor Fitzgerald
Feb 14
12:15am ET
Buy Rating Affirmed for Rezolute Amidst Promising Clinical Developments and Stable Financials
Feb 13
4:10pm ET
Rezolute reports Q2 EPS (27c), consensus (30c)
Feb 08
6:19am ET
Buy Rating Affirmed for Rezolute’s RZ358 Based on Untapped Market Potential and Therapeutic Efficacy
Jan 24
8:09am ET
Rezolute appoints Evans as Chief Financial Officer
Jan 23
8:12am ET
Rezolute receives Innovative Passport designation from MHRA for RZ358
RZLT Financials
Key terms
Ad Feedback
RZLT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RZLT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
